Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 2/2019

01-04-2019 | Original Article

Impact of Genotype of Beta Globin Gene on Hepatic and Myocardial Iron Content in Egyptian Patients with Beta Thalassemia

Authors: Tamer H. Hassan, Mohamed M. Abdel Salam, Marwa Zakaria, Mohamed Shehab, Dina T. Sarhan, El Sayed H. Zidan, Khaled M. El Gerby

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2019

Login to get access

Abstract

Iron overload causes most of the mortality and morbidity associated with thalassemia. Excess iron deposits primarily in the liver, but once a threshold level is reached, iron loading may occur in other tissues such as the heart. Magnetic resonance imaging is a well established technique to noninvasively quantify myocardial and liver iron content. More than 300 disease-causing mutations have been identified. We aimed to determine the impact of genotype on liver iron content in patients with beta thalassemia. Cross sectional study was carried on 73 patients with beta thalassemia. MRI liver and heart was performed to determine hepatic and myocardial iron overload. Genotyping was determined by DNA sequencing technique. The mean liver iron content was 17.4 mg/g dw and mean cardiac T2* was 25.5 ms in our patients. Patients with β0β0 were associated with significantly higher liver and myocardial iron content compared to those with β0β+ and β+β+ genotypes. There was a clear association between genotype and both hepatic and myocardial iron overload. Patients with β0β0 had significantly higher liver and heart iron content compared to those with β0β+ and β+β+ genotypes. Liver iron content was strongly correlated to serum ferritin levels and myocardial iron overload.
Literature
1.
Finotti A, Gambari R (2014) Recent trends for novel options in experimental biological therapy of β-thalassemia. Expert Opin Biol Therapy 14:1443–1454CrossRef
2.
El-Beshlawy A, Kaddah N, Moustafa A, Mouktar G, Youssry I (2007) Screening for beta-thalassaemia carriers in Egypt: significance of the osmotic fragility test. East Mediterr Health J 13:780–786PubMed
3.
Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W et al (2007) Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol 82:255–265CrossRefPubMed
4.
Singer ST (2009) Variable clinical phenotypes of alpha-thalassemia syndromes. Sci World J 9:615–625CrossRef
5.
Deborah Chirnomas S, Geukes-Foppen M, Barry K, Braunstein J, Kalish LA, Neufeld EJ et al (2008) Practical implications of liver and heart iron load assessment by T2*-MRI in children and adults with transfusion-dependent anemias. Am J Hematol 83:781–783CrossRefPubMed
6.
Hankins JS, McCarville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA et al (2009) R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 113:4853–4855CrossRefPubMedCentralPubMed
7.
Cheng HL, Holowka S, Moineddin R, Odame I (2012) Liver iron overload assessment by T magnetic resonance imaging in pediatric patients: an accuracy and reproducibility study. Am J Hematol 87:435–439CrossRefPubMed
8.
Abdulzahra MS, Al-Hakeim HK, Ridha MM (2011) Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients. Asian J Transfus Sci 5:127–131CrossRefPubMedCentralPubMed
9.
Najafipour F (2008) Evaluation of endocrine disorders in patients with thalassemia major. Int J Endocrinol Metab 2:104–113
10.
Chen W, Zhang X, Shang X, Cai R, Li L, Zhou T et al (2010) The molecular basis of beta-thalassemia intermedia in southern China: genotypic heterogeneity and phenotypic diversity. BMC Med Genet 11:31CrossRefPubMedCentralPubMed
11.
Novelletto A, Hafez M, Deidda G, Di Rienzo A, Felicetti L, el-Tahan H et al (1990) Molecular characterization of beta-thalassemia mutations in Egypt. Hum Genet 85:272–274CrossRefPubMed
12.
Hussein IR, Temtamy SA, el-Beshlawy A, Fearon C, Shalaby Z, Vassilopoulos G et al (1993) Molecular characterization of beta-thalassemia in Egyptians. Hum Mutat 2:48–52CrossRefPubMed
13.
Omar A, Abdel Karim E, Gendy WE, Marzouk I, Wagdy M (2005) Molecular basis of beta-thalassemia in Alexandria. Egypt J Immunol 12:15–24PubMed
14.
Hussein G, Fawzy M, Serafi TE, Ismail EF, Metwally DE, Saber MA et al (2007) Rapid detection of beta-thalassemia alleles in Egypt using naturally or amplified created restriction sites and direct sequencing: a step in disease control. Hemoglobin 31:49–62CrossRefPubMed
15.
Jiffri EH, Bogari N, Zidan KH, Teama S, Elhawary NA (2010) Molecular updating of β-thalassemia mutations in the upper Egyptian population. Hemoglobin 34:538–547CrossRefPubMed
16.
Soliman OE, Yahia S, Shouma A, Shafiek HK, Fouda AE, Azzam H et al (2010) Reverse hybridization StripAssay detection of beta-thalassemia mutations in northeast Egypt. Hematology 15:182–186CrossRefPubMed
17.
Al-Akhras A, Badr M, El-Safy U, Kohne E, Hassan T, Abdelrahman H et al (2016) Impact of genotype on endocrinal complications in β-thalassemia patients. Biomed Rep 4:728–736CrossRefPubMedCentralPubMed
18.
Huisman THJ, Carver MFH, Baysal E (1997) Beta-thalassemia; nondeletional mutants. In: Huisman THJ, Carver MFH, Baysal E, Marianne FH (eds) A syllabus of thalassemia mutations. The Sickle Cell Anemia Foundation, Augusta, pp 1–309
19.
Elmezayen AD, Kotb SM, Sadek NA, Abdalla EM (2015) β-globin mutations in Egyptian patients with β-thalassemia. Lab Med 46:8–13CrossRefPubMed
20.
El-Shanshory M, Hagag A, Shebl S, Badria I, Abd Elhameed A, Abd El-Bar E et al (2014) Spectrum of beta globin gene mutations in Egyptian children with β-thalassemia. Mediterr J Hematol Infect Dis 6:e2014071CrossRefPubMedCentralPubMed
21.
Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD (2004) Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 103:1934–1936CrossRefPubMed
22.
Eghbali A, Taherahmadi H, Shahbazi M, Bagheri B, Ebrahimi L (2014) Association between serum ferritin level, cardiac and hepatic T2-star MRI in patients with major β-thalassemia. Iran J Ped Hematol Oncol 4:17–21PubMedCentralPubMed
23.
Fragasso A, Ciancio A, Mannarella C, Gaudiano C, Scarciolla O, Ottonello C et al (2011) Myocardial iron overload assessed by magnetic resonance imaging (MRI)T2* in multi-transfused patients with thalassemia and acquired anemias. Eur J Intern Med 22:62–65CrossRefPubMed
24.
Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM et al (2014) A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood 123:1447–1454CrossRefPubMedCentralPubMed
25.
Casale M, Meloni A, Filosa A, Cuccia L, Caruso V, Palazzi G et al (2015) Multiparametric cardiac magnetic resonance survey in children with thalassemia major: a multicenter study. Circ Cardiovasc Imaging 8:e003230CrossRefPubMed
26.
Verlhac S, Morel M, Bernaudin F, Béchet S, Jung C, Vasile M (2015) Liver iron overload assessment by MRI R2* relaxometry in highly transfused pediatric patients: an agreement and reproducibility study. Diagn Interv Imaging 96:259–264CrossRefPubMed
27.
Chern JP, Lin KH, Tsai WY, Wang SC, Lu MY, Lin DT et al (2003) Hypogonadotropic hypogonadism and hematologic phenotype in patients with transfusion-dependent beta-thalassemia. J Pediatr Hematol Oncol 25:880–884CrossRefPubMed
28.
Skordis N, Michaelidou M, Savva SC, Ioannou Y, Rousounides A, Kleanthous M et al (2006) The impact of genotype on endocrine complications in thalassaemia major. Eur J Haematol 77:150–156CrossRefPubMed
29.
Yaman A, Isik P, Yarall N, Kardemir S, Cetinkaya S, Bay A et al (2013) Common complications in beta thalasemia patients. Int J Hematol Oncol 3:193–199CrossRef
30.
Winichagoon P, Fucharoen S, Chen P, Wasi P (2000) Genetic factors affecting clinical severity in beta-thalassemia syndromes. J Pediatr Hematol Oncol 22:573–580CrossRefPubMed
31.
Kattamis C, Metaxotou-Mavromati A, Ladis V, Tsiarta H, Laskari S, Kanavakis E (1982) The clinical phenotype of beta and delta beta thalassemias in Greece. Eur J Pediatr 139:135–138CrossRefPubMed
32.
Galanello R, Cao A (1998) Relationship between genotype and phenotype. Thalassemia intermedia. Ann N Y Acad Sci 850:325–333CrossRefPubMed
33.
Shamoon RP, Al-Allawi NA, Cappellini MD, Di Pierro E, Brancaleoni V, Granata F (2015) Molecular basis of β-thalassemia intermedia in Erbil province of Iraqi Kurdistan. Hemoglobin 39:178–183CrossRefPubMed
34.
Camaschella C, Mazza U, Roetto A, Gottardi E, Parziale A, Travi M et al (1995) Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol 48:82–87CrossRefPubMed
35.
Majd Z, Haghpanah S, Ajami GH, Matin S, Namazi H, Bardestani M et al (2015) Serum ferritin levels correlation with heart and liver MRI and LIC in patients with transfusion-dependent thalassemia. Iran Red Crescent Med J. 17:e24959CrossRefPubMedCentralPubMed
36.
Karimi M, Amirmoezi F, Haghpanah S, Ostad S, Lotfi M, Sefidbakht S et al (2016) Correlation of serum ferritin levels with hepatic MRI T2 and liver iron concentration innontransfusion betathalassemia intermediate patients: a contemporary issue. Blood 128:4829
37.
Pepe A, Meloni A, Casale M, Neri MG, Bitti PP, Macchi S et al (2015) Association between serum ferritin and liver iron concentration with cardiac iron in pediatric thalassemia major patients. Blood 126:956
38.
Keikhaei B, Khosravi A, Nojoumi S, Slehi-fard P (2017) Relationship between serum ferritin and hemoglobin levels determined by cardiac and hepatic T2 MRI in beta-thalassemia intermedia and major patients. Front Biol 12:311–315CrossRef
39.
Yuksel IO, Koklu K, Kurtoglu E, Arslan S, Cagirci G, Karakus V et al (2016) The association between serum ferritin level, tissue doppler echocardiography, cardiac T2* MRI, and heart rate recovery in patients with beta thalassemia major. Acta Cardiol Sin 32:231–238PubMedCentralPubMed
40.
Azarkeivan A, Hashemieh M, Akhlaghpoor S, Shirkavand A, Yaseri M, Sheibani K (2013) Relation between serum ferritin and liver and heart MRI T2* in beta thalassaemia major patients. East Mediterr Health J 19:727–732CrossRefPubMed
Metadata
Title
Impact of Genotype of Beta Globin Gene on Hepatic and Myocardial Iron Content in Egyptian Patients with Beta Thalassemia
Authors
Tamer H. Hassan
Mohamed M. Abdel Salam
Marwa Zakaria
Mohamed Shehab
Dina T. Sarhan
El Sayed H. Zidan
Khaled M. El Gerby
Publication date
01-04-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-018-1034-x

Other articles of this Issue 2/2019

Indian Journal of Hematology and Blood Transfusion 2/2019 Go to the issue

Original Article

Reduced Dose Ibrutinib Due to Financial Toxicity in CLL

Original Article

Outcome of Philadelphia Positive Acute Lymphoblastic Leukemia With or Without Allogeneic Stem Cell Transplantation in a Retrospective Study

Correspondence

Haemorrhagic Bulla: A Rare Presentation of Acute Lymphoblastic Leukemia

Correspondence

Rare Presentations of Acute Lymphoblastic Leukemia

Original Article

Does Transfusion of Blood and Blood Products Increase the Length of Stay in Hospital?

Correspondence

Leukemia Cutis: A Rare Initial Presentation of Chronic Lymphocytic Leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits